Coronary Angiography, Glucagon-like Peptide-1
Conditions
Brief summary
GLP-1(9-36) amide and (9-37), which was previously thought to be the inactive metabolite of GLP-1, also exerts cardioprotective effects. Direct administration of GLP-1(9-36) during reperfusion reduced ischaemic damage in isolated hearts and increased cGMP release, vasodilatation and coronary flow in AMI mouse model, one may speculate that total GLP-1 level may associate with adverse cardiovascular events in AMI patients, the hypothesis is therefore tested in this study.
Interventions
DIAGNOSTIC_TESTplasma glucagon-like peptide-1 levels
The plasma GLP-1 levels was determined by enzymatic assays.
Sponsors
Chinese PLA General Hospital
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* consecutive patients of acute AMI come to our department,absent of cardiogenic shock, and survival for at least 24 h after PCI treatment.
Exclusion criteria
* patients with cancer, and patients who were taking a DPP4 inhibitor or a glucagon-like peptide-1 (GLP-1) analogue
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| all-cause mortality | The median follow-up was 29 months |
| cardiovascular mortality | The median follow-up was 29 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| heart failure readmission | The median follow-up was 29 months | readmission to any hospital due to diagnosed heart failure |
| non-cardiovascular mortality | The median follow-up was 29 months | — |
| repeated revascularization | The median follow-up was 29 months | defined as repeated PCI or bypass grafting of not only infarct related artery |
| Stroke | The median follow-up was 29 months | defined using the World Health Organization criteria |
| Myocardial infarction | The median follow-up was 29 months | — |
Outcome results
None listed